Albireo Pharma — Investor Presentation (December 2016)
40 slides from Albireo Pharma's investor presentation, Dec 21, 2016
Slide 1: Corporate Presentation
Exhibit 99.1 Corporate Presentation December 21, 2016
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Certain Securities not looking “intends,” harbor in into endpoints, advance or program other and consider property; IBAT regulatory All obligation “Albireo” 2©2016 trial the elobixibat to forward-looking uncertainties Europe; a product inhibitors statements pivotal place of provisions Alb
Slide 3: Innovative Albireo Leader in Bile Acid Modulators
Innovative Albireo Leader Three Strong AstraZeneca Transaction Highly 3©2016clinical patent Albireo in experienced the Science provided spinout development portfolio, assets, Pharma, +management in including Deep approximately 2008; with Inc.of Pipeline All orphan bile became lead rights team acid P
Slide 4: Experienced Management Team
DeepClinical Ron President (President BMS Cubist, SVP, Santaris, Paresh Alexion, Chief Aegerion, AstraZeneca, VP, ©2016 4AstraZeneca Development Cooper Corporate Biotech Operating Financial Medical Regulatory Soni Albireo Euthymics, Amarin, Targacept and Proteon, ofMBChB, Affairs Tom Europe) Pharmac
Slide 5: A Robust Pipeline
A Robust Lead A4250 PFIC Additional Elobixibat Partnered IBAT A3384 Preclinical Bile NASH Inflammatory Orphan 5©2016 Acid Program inhibitor Albireo Ph2 Modulators NKPipeline Cholestyramine inChronic Programs: Clinical pediatric antagonist Japan/US/EU Bowel Preclinical Other Constipation Pharma, Targ
Slide 6: Investment Thesis
Pediatric Novel, A4250 Elobixibat Partnering Voucher 6©2016 First-in-Class Albireo Novel NASH Orphan BAM partnering Bile Pharma, Development Opportunities Acid Product in PPAR Japan Inc. All Candidate Ph3 (positive US/EU Provide rights CICA3384 reserved. Ph3 Foundation to Treat trial) Pediatric Mult
Slide 7: Significant Near-Term News Flow
Significant Event Elobixibat: A4250: 7©2016Projected Albireo PRIME FDA report News report JNDA meeting additional data Pharma, designation Timing Flow data filing fromQ1 from and Inc. Q1 planned pediatric 2017 Near-Term 2017 granted ongoing All rights pivotal data by Ph3 reserved. Milestones from EM
Slide 8: A4250 for Orphan Pediatric Liver Diseases
A4250 for Orphan Pediatric Liver Diseases
Slide 9: A4250 Potential First Approved Drug in Progressive Familial Intrahepatic Cholestasis
Potential Progressive A4250 Multiple Elevated Positive The Orphan *includes 9©2016 market science… exclusivity Albireo designation effects pediatric serum to estimated opportunity… Become Familial Pharma, on bile period… orphan serum in H-W acids First Intrahepatic PFIC Inc. bile PTE Drug liver link
Slide 10: IBAT Inhibitors Reduce Serum Bile Acids
~ 95%known Inhibitors Reduced Increased Decreased Serum *also ©2016 10 Bile of Albireo liver bile colonic selectively pruritus Acids asacids and Pharma, apical secretion serum and (BA) reduce sodium-dependent decreased Inc. bile pumped and All BA acids motility rights re-uptake cholesterol; from to
Slide 11: Bile Acid Accumulation Induces Liver Cell Death
Bile Acid Perez ©2016 11 World Albireo Accumulation J Gastroenterol. Pharma, Inc. Induces All 2009rights Liver Apr reserved. Cell 14;15(14):1677-89. Death, Key in Pathogenesis of PFIC
Slide 12: Estimated PFIC Patients and Treatment Options
Estimated No Symptoms A4250 Median pruritus Treatment Medical: Often Survival ©2016 12 Approved leads Albireo onset relief off ~10,000 options: develop tolabel 2Drug is liver Pharma, months theUDCA, PFIC to failure early Options goal address Severe Inc. of Patients inrifampin, by early children for
Slide 13: Rationale for A4250 in PFIC: Benefits of PEBD
Benefits Rationale A4250 Surgical PEBD Long-term One Before Bile Bilirubin Itching ©2016 13 Acids Year normalizes Albireo Surgery (0-5) procedure of (umol/L) for (umol/L) benefits Bile 3IBAT 1Pharma, After Diversion serum 41 to of Inhibition 337 Surgery permanently 25 PEBD Inc. 11 bile Surgery All i
Slide 14: Proof of Principle: Preclinical and Early Clinical Data
*14 Proof A4250 ?Preclinical 1000 300 350 800 250 400 20 Liver *p<0 150 ALT: ALP: *p< **p< 600 7Control Stat. ©2016 ALT ofAlbireo 0.05 sig.Enzymes 100 200 * Principle 0.05 0.01 (U/L) and Cholestatic weeks alanine alkaline A4250 days 200Early ALP *?all and Serum 50doses 4Pharma, weeks Clinical (U/L)
Slide 15: A4250 Investigator-Initiated Study in PBC
A4250 Data Investigator-Initiated Crossover 1.5mg Initial 50% All 1.5 ©2016 15 mg treated mean Shows Findings A4250 Albireo Study 3 mgdesign, patients ? Substantial serum 3in QD mg Pharma, Encouraging Adults for 3x4 n=5 with bile Ph2 1weeks n=4 with wk acids, Reduction Inc. pruritus Primary +n=3 PBC
Slide 16: Ongoing Phase 2 Study Design
716 Ongoing Designed A4250 Assess Objectives Key Diagnosis (e.g., VAS-itch Primary Number Secondary Pruritus Open -Baseline—Single Sprinkle Up Four-week Cohort toinclusion PFIC, label, Cohorts ©2016 24 aparameters; endpoints sites of dose formulation wide Phase subjects ?to of endpoints treatment-em
Slide 17: A4250 Phase 2 Study Outline
A4250 *Ph2 Outline Pediatric ©2016 17 Wash-out AlbireoStudy: in caseInc. Pharma, of All bilerights acid resin or other prohibited medication use of 7 days required PK reserved.
Slide 18: A4250 Phase 2 Patient Demographics and Dose Summary
A4250 Albireo ©2016 18 Patient Demographics Pharma, Inc. All andrights Dosereserved. Summary
Slide 19: A4250 Serum Bile Acid Reduction
A4250 Reduction S 0eno lin —4 nMean -%—8 *would Cohort ± 0.01 0.3 ©2016 19117-year aindicates eBSEP e0emg r0s—2 mg/kg umesBA 0 0m Albireo Ph2 1gnot 0.7Cohort function* bnold 0of reduction mg Standard ile ameet Pediatric 0.03 a hSerum with ba1.4 c—6 Pharma, .cmg/kg 2sexpected id vlow Cohort mgsBile 0
Slide 20: Serum Bile Acid Reduction in PFIC Patients
420 Ph2 in A4250 Mean s s0SaSerum 0S B PFIC dsPediatric includes ©2016 sBA 0Cohorts 3e(n=9) 0linBile 0eid AlbireoReduction 3Study: A4Acids PFIC i0cin 0Pharma, 201-5 5(n=7,Particularly Bc PFIC (including Patients anontarget Inc. )s )eaAll lin L /LRobust eearly rights A4 PFIC 0Reduction e l/2cohorts i
Slide 21: A4250 Favorable Pruritus and Sleep Outcomes
0.01 A4250 Favorable Measure Ph2 –mg/kg Whitington Pruritus Sleep Mean SCORAD ± ©2016 21 Cohort indicatesPruritus Pediatric –change Dose Albireo PO- VAS 0.03 PO—1.000.03 1Baseline Standard 0.3 +0.12 Cohort Outcomes -1.41 mg0.36 ± mg/kg Study: vs±Pharma, 0.7 Error ± 0.68 2of ±-0.33 0.85 mg 1.10 Inc.0
Slide 22: Reduction of Serum Bile Acids Correlates with Pruritus Reduction
37hpe% Demonstrated hPruritus 1 4Sleep S 7A nc25V Itc to g2d5pcre19* 2e0 — VAS 5sh0aasPO-SCORAD n 19* Correlation aPruritus cc— Between Whitington Reduction of Serum Bile A4250 Acids and Reduction of Pruritus Reinforces Link --2 decr1Ppd-1 3O lta -2 % *n 0-1 ©2016 22 detin 0l= <=cd d5n-2 na= e02in =
Slide 23: A4250 Safety and Tolerability
Ph2diarrhea Safety A4250 No Some DSMB ©2016 23 treatment-emergent dropouts Pediatric increases and Albireo permits Tolerability during and Study Pharma, continuation inadverse liver 4-week Cohorts Data serious enzymes, Inc. events dosing All of 1-5: adverse dosing generally rights no period; meaning
Slide 24: A4250 Staged Development Approach
A4250 Alagille Biliary POC* (Primary Ph2 Development *POC= Disease Primary ©2016 24 Ph2 in Albireo Staged (PRO) Proof Syndrome Sclerosing Pruritus Adults Biliary Liver of Atresia Clinical Pharma, Cholestatic Concept Liver Pruritus Cholangitis Disease Development Inc. in Tool Ped. AllPFIC rights Chol
Slide 25: Planned Pivotal Trial and Approval Path in PFIC
Subpart Seek Planned supported Secondary/Exploratory Long-term FDA EU ©2016 25 PRIME accelerated meeting Albireo H primary by Approval outcome designation Phase planned Pharma, endpoint: approval 2study for sBA Q1 endpoints: PFIC granted Inc. 2017 to for and sBA All be with PFIC pruritus underway re
Slide 26: A4250 Differentiated IBAT Inhibitor
326 A4250 Serum HO S OH NHoCH H3C CH N O Cl NH H OCSO H3C Sources: 50 Sbile A NH + NCHDifferentiated -N O CONFIDENTIAL. cation 3acids H3C OH N AUC CH3 NPermanent Graffner 0-15h et©2016 al. IBAT cation Day Inhibitor Aliment Albireo IC 14 (human) Pharmacol Limited. 0.13Ther All nMrights 2016 IC50reser
Slide 27: Shire SHP625 Variability and A4250 Highlights
13 Variability Highlight A4250 PFIC Did significant normalized acidsnot Subset 12.1% PSC Alagille performed and Following out The Potent *various ©2016 27 all meet ofweeks, Need of PBC Albireo in improvement baseline 1° Phase PFIC-2 pruritus better future Compound Albireo Shire theSBAfor interim end
Slide 28: A4250 Multiple Pediatric Orphan Opportunities
A4250 A Multiple Pediatric Biliary Attractive Favorable *Estimated ©2016 28 Albireo Atresia Rare Cholestatic Compelling Orphan Competitive prevalence Diseases Pruritus Pharma, Pricing Commercial data Landscape with Inc. and derived All No Reimbursement Approved rights May Opportunity based reserved.
Slide 29: Pipeline Programs
Pipeline Programs Elobixibat CIC Ph3 A3384 BAM Ph2 NASH Preclinical
Slide 30: Elobixibat First-in-Class Opportunity in CIC
First Increases Elobixibat 156% oStrong The Composition *includes ©2016 30Differentiated market data… commercial exclusivity and dollar US Albireo Only Both estimated Ph2b opportunity… Rx ofLarge Secretion Pharma, period… matter market by efficacy potential… mechanism’s H-W Bowel-Acting togrowth Inc
Slide 31: Elobixibat Licensed and in Phase 3
in Ph3 Elobixibat Licensed License Approximately Positive Primary All Change No EA Ph2b US/EU Ph3 *plus ©2016 31 SAEs; Pharma secondary (US/EU (US): five Trial Albireo in follows Endpoint endpoint Phase toother substantially weekly complete primary expected EA In ex-licensee): efficacy 3Japan Pharma
Slide 32: A3384 Bile Acid Malabsorption Phase 2
*32 Positioned The Phase Designed BAM science… Earlier stages ©2016 2Albireo BAM p to <market to0.05 commercialdeliver exclusivityBecome Study generation opportunity… cholestyramine Pharma,First period… potential… Drug formulation Inc. Elevated Approved Formulation directly Blockbuster Allproves rig
Slide 33: NASH Platform Data
©2016Placebo Reduction 35,00 Col1_1 Principal Albireo Col1_2 Hallmarks of Pro-Inflammatory 15 Pharma, * *mg Relative Improvement 20 Inc.. mg GLP1 expression AllMarkers rights in pmol/L Fibrotic reserved. K19 (preclin) * *Markers *p<0.05 Decreased * Tnf-_ (preclin) *p<0.05 Insulin Mcp1IBAT Baghdasary
Slide 34: A4250 NASH Preclinical Data
IBAT A4250 10 Mean Presented p<0.05 Kremoser Candidate ©2016 34 mg/kg, Significant ±Albireo OCA SDat et Screening 3 wks 2016 al. OCA Pharma, 9th 10 NAS DDW Significantly JSH mg/kg, forReduction Inc. Single Novel Meeting 5All wks Topic Bile Reduces rights OCA with 25Acid mg Conference: reserved. A425
Slide 35: Summary
Albireo<
Slide 36: Investment Thesis
Pediatric Novel, A4250 Elobixibat Partnering Voucher ©2016 36 First-in-Class Albireo Novel NASH Orphan BAM partnering Bile Pharma, Development Opportunities Acid Product in PPAR Japan Inc. All Candidate Ph3 (positive US/EU Provide rights CICA3384 reserved. Ph3 Foundation to Treat trial) Pediatric Mu
Slide 37: Strong Patent Portfolio and Regulatory Protections
Strong Est. liver Elobixibat Composition A3384 Formulation *H-W ©2016 37 H-W diseases PTE Patent Albireo USPTE* US Expiry for (pending) of (pending) and Expiry one Pharma, Matter + A4250 Regulatory Est. patent Est. H-W February August September Orphan Inc. USper H-W PTE* All Expiry Protections produ
Slide 38: Significant Near-Term News Flow
Significant Event Elobixibat: A4250: ©2016 38 Projected Albireo PRIME FDA report News report JNDA meeting additional data Pharma, designation Timing Flow data filing fromQ1 from and Inc. Q1 planned pediatric 2017 Near-Term 2017 granted ongoing All rights pivotal data by Ph3 reserved. Milestones from
Slide 39: Innovative Albireo Leader in Bile Acid Modulators
Innovative Albireo Leader Three Strong AstraZeneca Highly ©2016 39 clinical patent Albireo in experienced the Science spinout; development portfolio, assets, Pharma, +management including Deep aswith Inc. of of Nov Pipeline All orphan bile lead 2016, rights team acid Phase +drug Experienced listed r
Slide 40: Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation
Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation
Albireo Pharma — Investor Presentation (December 2016) on 6ix